Results 151 to 160 of about 5,411 (177)

Iron chelation as a new therapeutic approach to prevent senescence and liver fibrosis progression. [PDF]

open access: yesCell Death Dis
Amengual J   +11 more
europepmc   +1 more source

Mitochondrial dysfunction, iron accumulation, lipid peroxidation, and inflammasome activation in cellular models derived from patients with multiple sclerosis. [PDF]

open access: yesAging (Albany NY)
García-Salas R   +10 more
europepmc   +1 more source

Amelioration of nephrotoxicity by targeting ferroptosis: role of NCOA4, IREB2, and SLC7a11 signaling. [PDF]

open access: yesBraz J Med Biol Res
Sharawy N   +7 more
europepmc   +1 more source

Deferiprone

Annals of the New York Academy of Sciences, 2010
Deferiprone (DFP) has been evaluated in a wide range of disorders, but most data come from transfusion‐dependent thalassemia. The safety and tolerability profile includes gastrointestinal complaints, liver enzymes elevation, weight gain, arthropathy, neutropenia, and agranulocytosis.
PIGA, Antonio Giulio   +5 more
openaire   +3 more sources

Deferiprone: New Insight

Annals of the New York Academy of Sciences, 2005
Abstract: Recent results from independent studies suggest that deferiprone is more cardioprotective than deferoxamine. Patients on long‐term treatment with deferiprone have a better myocardial magnetic resonance imaging pattern and less chance to develop a new cardiac disease or worsen an existing one.
PIGA, Antonio Giulio   +5 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy